Linnaeus Therapeutics, Inc.

Biotech Haddonfield, NJ

About

Issuer

Entity type
Corporation
Jurisdiction
Delaware
Sector
Biotech
Headquarters
Haddonfield, NJ
Street
30 Washington Avenue, Suite F
Zip
08033

Offering

Total offering
$10M
Amount sold
$4.9M
First sale
Feb 17, 2026
Min investment
$1
Securities
Equity
Federal exemption
Rule 506(b)
Investors so far
26

How this filing compares

Ranked #7 of 23 Biotech filings in March 2026 by offering amount.

Median Biotech filing in March 2026: $5.4M. This offering is 1.8× the median.

Other New Jersey filings this week: Hulfish Lane finCap Partners LP, Straka Partners, LLC, CPIF Sparti SAF, L.P., FlexPath EB-5 Fund 1 LLC, Lord Abbett Private Credit Fund S

Leadership

Patrick Mooney — Executive Officer (also: Director)

James Demetriades — Director

Also named on: Provivi, Inc.

Michael Poisel — Director

Chris Arendt — Director

Todd Thomson — Director

John Lepping — Director

Filing details

Linnaeus Therapeutics, Inc. filed a Form D with the SEC on March 31, 2026.

Other newest Biotech companies

Other newest companies in New Jersey